As our results reveal that the percentage of PD‐1+ CD8 cells in the tumor as well as the frequency of PD-L1-expressing tumor cells were reduced at the end of therapy, neoadjuvant or simultaneous anti-PD‐1 or anti-PD-L1 treatment might provide better treatment efficiency in upcoming clinical studies. This evidence concerns the gene CD8A and neoplasm.